Sophie Quoilin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sophie Quoilin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Amber Litzroth
Scientific Directorate Epidemiology and Public Health Sciensano, Juliette Wytsmanstraat 14, 1050 Brussels, Belgium
2 shared publications - Benoît Kabamba-Mukadi
Department of Microbiology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
2 shared publications - Annie Robert
Affiliation Institut de Recherche Expérimentale et Clinique, Pôle Epidémiologie et Biostatistique, Université catholique de Louvain (UCLouvain), Brussels, Belgium
1 shared publication - Brecht Devleesschauwer
Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium; Department of Translational Physiology, Infectiology and Public Health, Ghent University, Merelbeke, Belgium
1 shared publication - Chloé Wyndham-Thomas
Scientific directorate Epidemiology and public health, Sciensano, Juliette Wytsmanstreet 14, 1050, Brussels, Belgium
1 shared publication - Gaëtan Muyldermans
Epidemiology and Public Health, Sciensano, Brussels, Belgium
1 shared publication
Latest Publications
- Open Access
- 31 August 2020
- Published by Springer Nature in BMC Public Health
- Vol. 20 (1) , 1-18
Perceived utility and feasibility of pathogen genomics for public health practice: a survey among public health professionals working in the field of infectious diseases, Belgium, 2019
Background: Pathogen genomics is increasingly being translated from the research setting into the activities of public health professionals operating at different levels. This survey aims to appraise the literacy level and gather the opinions of public health experts and allied professionals working in the field of infectious diseases in Belgium concerning the implementation of next-generation sequencing (NGS) in public health practice. Methods: In May 2019, Belgian public health and healthcare professionals were invited to complete an online survey containing eight main topics including background questions, general attitude towards pathogen genomics for public health practice and main concerns, genomic literacy, current and planned NGS activities, place of NGS in diagnostic microbiology pathways, data sharing obstacles, end-user requirements, and key drivers for the implementation of NGS. Descriptive statistics were used to report on the frequency distribution of multiple choice responses whereas thematic analysis was used to analyze free text responses. A multivariable logistic regression model was constructed to identify important predictors for a positive attitude towards the implementation of pathogen genomics in public health practice. Results: 146 out of the 753 invited public health professionals completed the survey. 63% of respondents indicated that public health agencies should be using genomics to understand and control infectious diseases. Having a high level of expertise in the field of pathogen genomics was the strongest predictor of a positive attitude (OR = 4.04, 95% CI = 1.11 – 17.23). A significantly higher proportion of data providers indicated to have followed training in the field of pathogen genomics compared to data end-users (p < 0.001). Overall, 79% of participants expressed interest in receiving further training. Main concerns were related to the cost of sequencing technologies, data sharing, data integration, interdisciplinary working, and bioinformatics expertise. Conclusions: Belgian health professionals expressed favorable views about implementation of pathogen genomics in their work activities related to infectious disease surveillance and control. They expressed the need for suitable training initiatives to strengthen their competences in the field. Their perception of the utility and feasibility of pathogen genomics for public health purposes will be a key driver for its further implementation.
- 31 August 2020
- Published by Springer Nature in BMC Public Health
- Vol. 20 (1) , 1-18
Open AccessPerceived utility and feasibility of pathogen genomics for public health practice: a survey among public health professionals working in the field of infectious diseases, Belgium, 2019
Background: Pathogen genomics is increasingly being translated from the research setting into the activities of public health professionals operating at different levels. This survey aims to appraise the literacy level and gather the opinions of public health experts and allied professionals working in the field of infectious diseases in Belgium concerning the implementation of next-generation sequencing (NGS) in public health practice. Methods: In May 2019, Belgian public health and healthcare professionals were invited to complete an online survey containing eight main topics including background questions, general attitude towards pathogen genomics for public health practice and main concerns, genomic literacy, current and planned NGS activities, place of NGS in diagnostic microbiology pathways, data sharing obstacles, end-user requirements, and key drivers for the implementation of NGS. Descriptive statistics were used to report on the frequency distribution of multiple choice responses whereas thematic analysis was used to analyze free text responses. A multivariable logistic regression model was constructed to identify important predictors for a positive attitude towards the implementation of pathogen genomics in public health practice. Results: 146 out of the 753 invited public health professionals completed the survey. 63% of respondents indicated that public health agencies should be using genomics to understand and control infectious diseases. Having a high level of expertise in the field of pathogen genomics was the strongest predictor of a positive attitude (OR = 4.04, 95% CI = 1.11 – 17.23). A significantly higher proportion of data providers indicated to have followed training in the field of pathogen genomics compared to data end-users (p < 0.001). Overall, 79% of participants expressed interest in receiving further training. Main concerns were related to the cost of sequencing technologies, data sharing, data integration, interdisciplinary working, and bioinformatics expertise. Conclusions: Belgian health professionals expressed favorable views about implementation of pathogen genomics in their work activities related to infectious disease surveillance and control. They expressed the need for suitable training initiatives to strengthen their competences in the field. Their perception of the utility and feasibility of pathogen genomics for public health purposes will be a key driver for its further implementation.
- Open Access
- 23 July 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 1-18
Incidence estimation from sentinel surveillance data; a simulation study and application to data from the Belgian laboratory sentinel surveillance
Inverse probability weighting (IPW) methods can be used to estimate the total number of cases from the sample collected through sentinel surveillance. Central to these methods are the inverse weights which can be derived in several ways and, in this case, represent the probability that laboratory (lab) sentinel surveillance detects a lab-confirmed case. We compare different weights in a simulation study. Weights are obtained from the proportion of participating labs over all labs. We adjust these weights for attractiveness and density of labs over population. The market share of sentinel labs, as estimated by the econometric Huff-model, is also considered. Additionally, we investigate the effect of not recognizing sentinel labs as sentinel labs when they report no cases. We estimate the bias associated with the different weights as the difference between the simulated number of cases and the estimate of this total from the sentinel sample. As motivating data examples, we apply an extended Huff-model to four pathogens under laboratory sentinel surveillance in Belgium between 2010 and 2015 and discuss the model fit. We estimate the total number of lab-confirmed cases associated with Rotavirus, influenza virus, Y. enterocolitica and Campylobacter spp.. The extended Huff-model takes the lab-concept, the number of reimbursements and the number of departments, lab-density, regional borders, distance and competition between labs in account. Estimates obtained with the Huff-model were most accurate in the more complex simulation scenarios as compared to other weights. In the data examples, several significant coefficients are identified, but the fit of the Huff-model to the Belgian sentinel surveillance data leaves much variability in market shares unexplained. The Huff-model allows for estimation of the spatial and population coverage of sentinel surveillance and through IPW-methods also for the estimation of the total number of cases. The Huff-model‘s gravity function allows us to differentiate inside an area while estimating from the full dataset. Our data examples show that additional data on the participation to surveillance and practices of labs is necessary for a more accurate estimation.
- 23 July 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 1-18
Open AccessIncidence estimation from sentinel surveillance data; a simulation study and application to data from the Belgian laboratory sentinel surveillance
Inverse probability weighting (IPW) methods can be used to estimate the total number of cases from the sample collected through sentinel surveillance. Central to these methods are the inverse weights which can be derived in several ways and, in this case, represent the probability that laboratory (lab) sentinel surveillance detects a lab-confirmed case. We compare different weights in a simulation study. Weights are obtained from the proportion of participating labs over all labs. We adjust these weights for attractiveness and density of labs over population. The market share of sentinel labs, as estimated by the econometric Huff-model, is also considered. Additionally, we investigate the effect of not recognizing sentinel labs as sentinel labs when they report no cases. We estimate the bias associated with the different weights as the difference between the simulated number of cases and the estimate of this total from the sentinel sample. As motivating data examples, we apply an extended Huff-model to four pathogens under laboratory sentinel surveillance in Belgium between 2010 and 2015 and discuss the model fit. We estimate the total number of lab-confirmed cases associated with Rotavirus, influenza virus, Y. enterocolitica and Campylobacter spp.. The extended Huff-model takes the lab-concept, the number of reimbursements and the number of departments, lab-density, regional borders, distance and competition between labs in account. Estimates obtained with the Huff-model were most accurate in the more complex simulation scenarios as compared to other weights. In the data examples, several significant coefficients are identified, but the fit of the Huff-model to the Belgian sentinel surveillance data leaves much variability in market shares unexplained. The Huff-model allows for estimation of the spatial and population coverage of sentinel surveillance and through IPW-methods also for the estimation of the total number of cases. The Huff-model‘s gravity function allows us to differentiate inside an area while estimating from the full dataset. Our data examples show that additional data on the participation to surveillance and practices of labs is necessary for a more accurate estimation.
- Open Access
- 17 May 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 597
The value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium
Serological surveillance, based on the measurement of the presence of specific antibodies in a given population, can be used in addition to traditional and routine disease surveillance methods. The added value of this has been largely documented for vaccine-preventable diseases, but to a lesser extent for vector-borne diseases. This study aimed to evaluate the utility of seroprevalence data as additional source of information on the epidemiology of Lyme borreliosis in Belgium. In total, 3215 residual blood samples collected in 2013–2015 were analysed with Liaison® Borrelia IgG kit (DiaSorin S.p.A, Saluggia, Italy). Positive and equivocal results were further examined with immunoblotting (recomLine Borrelia IgG kit, Mikrogen, Neuried, Germany). Crude prevalence estimates of equivocal and seropositive results were calculated and further adjusted accounting for clustered sampling and standardized for age, sex and population per province, according to the Belgian population structure in 2014. The effect of age, sex and region on seropositivity was assessed using log-binomial regression. The overall weighted national seroprevalence for Borrelia burgdorferi sensu lato, adjusted for clustered sampling, age, sex and province was 1.06% (95%CI 0.67–1.67). Although not statistically significant, the highest prevalences were observed in men and in those younger than 15 years or older than 59 years of age. At provincial level, the seroprevalence estimates do not follow the geographical distribution of tick bites and diagnoses of Lyme borreliosis as detected through other surveillance systems. Although the use of residual samples for seroprevalence estimates has several advantages, it seems to be a limited tool for serological surveillance of Lyme borreliosis in Belgium, other than follow-up of trends if repeated over time. A population-based sampling strategy might provide a more representative nationwide sample, but would be very time intensive and expensive. Seroprevalence studies within risk groups or risk areas in Belgium could provide a useful alternative approach to complement routine surveillance data of Lyme borreliosis.
- 17 May 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 597
Open AccessThe value of seroprevalence data as surveillance tool for Lyme borreliosis in the general population: the experience of Belgium
Serological surveillance, based on the measurement of the presence of specific antibodies in a given population, can be used in addition to traditional and routine disease surveillance methods. The added value of this has been largely documented for vaccine-preventable diseases, but to a lesser extent for vector-borne diseases. This study aimed to evaluate the utility of seroprevalence data as additional source of information on the epidemiology of Lyme borreliosis in Belgium. In total, 3215 residual blood samples collected in 2013–2015 were analysed with Liaison® Borrelia IgG kit (DiaSorin S.p.A, Saluggia, Italy). Positive and equivocal results were further examined with immunoblotting (recomLine Borrelia IgG kit, Mikrogen, Neuried, Germany). Crude prevalence estimates of equivocal and seropositive results were calculated and further adjusted accounting for clustered sampling and standardized for age, sex and population per province, according to the Belgian population structure in 2014. The effect of age, sex and region on seropositivity was assessed using log-binomial regression. The overall weighted national seroprevalence for Borrelia burgdorferi sensu lato, adjusted for clustered sampling, age, sex and province was 1.06% (95%CI 0.67–1.67). Although not statistically significant, the highest prevalences were observed in men and in those younger than 15 years or older than 59 years of age. At provincial level, the seroprevalence estimates do not follow the geographical distribution of tick bites and diagnoses of Lyme borreliosis as detected through other surveillance systems. Although the use of residual samples for seroprevalence estimates has several advantages, it seems to be a limited tool for serological surveillance of Lyme borreliosis in Belgium, other than follow-up of trends if repeated over time. A population-based sampling strategy might provide a more representative nationwide sample, but would be very time intensive and expensive. Seroprevalence studies within risk groups or risk areas in Belgium could provide a useful alternative approach to complement routine surveillance data of Lyme borreliosis.
- Open Access
- 8 January 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 1-7
Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
Prevalence data of chronic hepatitis C virus (HCV) infection are needed to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAAs). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% from 1993 to 1994. In this first Belgian nationwide HCV prevalence study, we set out to update the seroprevalence and prevalence of chronic HCV infection estimates in the Belgian general population in order to guide decisions on DAA reimbursement. Residual sera were collected through clinical laboratories. We collected data on age, sex and district. HCV antibody status was determined with ELISA and confirmed with a line-immunoassay (LIA). In specimens with undetermined or positive LIA result, HCV viral load was measured. Specimens were classified seronegative, seropositive with resolved infection, indicative of chronic infection and with undetermined HCV status according to the test outcomes. Results were standardized for age, sex and population per district, and adjusted for clustered sampling. In total 3209 specimens, collected by 28 laboratories, were tested. HCV seropositivity in the Belgian general population was estimated to be 0.22% (95% CI: 0.09–0.54%), and prevalence of chronic HCV infection 0.12% (95% CI: 0.03–0.41). In individuals of 20 years and older, these estimates were 0.26% (95% CI: 0.10–0.64%) and 0.13% (95% CI: 0.04–0.43), respectively. Of the total estimated number of HCV seropositive individuals in Belgium, 66% were between 50 and 69 years old. Prevalence of HCV seropositivity and chronic infection in the Belgian general population were low and comparable to many surrounding countries. These adjusted prevalences can help estimate the cost of reimbursement of DAAs and invite Belgian policy makers to accelerate the scaling up of reimbursement, giving all chronically infected HCV patients a more timely access to treatment.
- 8 January 2019
- Published by Springer Nature in BMC Public Health
- Vol. 19 (1) , 1-7
Open AccessLow hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up
Prevalence data of chronic hepatitis C virus (HCV) infection are needed to estimate the budgetary impact of reimbursement of direct-acting antivirals (DAAs). In Belgium, the restricted reimbursement criteria are mainly guided by regional seroprevalence estimates of 0.87% from 1993 to 1994. In this first Belgian nationwide HCV prevalence study, we set out to update the seroprevalence and prevalence of chronic HCV infection estimates in the Belgian general population in order to guide decisions on DAA reimbursement. Residual sera were collected through clinical laboratories. We collected data on age, sex and district. HCV antibody status was determined with ELISA and confirmed with a line-immunoassay (LIA). In specimens with undetermined or positive LIA result, HCV viral load was measured. Specimens were classified seronegative, seropositive with resolved infection, indicative of chronic infection and with undetermined HCV status according to the test outcomes. Results were standardized for age, sex and population per district, and adjusted for clustered sampling. In total 3209 specimens, collected by 28 laboratories, were tested. HCV seropositivity in the Belgian general population was estimated to be 0.22% (95% CI: 0.09–0.54%), and prevalence of chronic HCV infection 0.12% (95% CI: 0.03–0.41). In individuals of 20 years and older, these estimates were 0.26% (95% CI: 0.10–0.64%) and 0.13% (95% CI: 0.04–0.43), respectively. Of the total estimated number of HCV seropositive individuals in Belgium, 66% were between 50 and 69 years old. Prevalence of HCV seropositivity and chronic infection in the Belgian general population were low and comparable to many surrounding countries. These adjusted prevalences can help estimate the cost of reimbursement of DAAs and invite Belgian policy makers to accelerate the scaling up of reimbursement, giving all chronically infected HCV patients a more timely access to treatment.